Sumanta Pal, Professor and Vice Chair of Academic Affairs at City of Hope, shared a post on LinkedIn:
“On behalf of Benjamin Garmezy, Ritesh Kotecha, Randy Sweis, M.D. & a team of terrific co-investigators, I am delighted to share the first data Xencor’s XmAb819, a first-in-class ENPP3xCD3 bispecific antibody. We have longed for new targets in kidney cancer beyond the VEGF-axis and checkpoint inhibition, and I am very encouraged by the responses we are seeing at the target dose range.
Much credit is due to the terrific clinical trials team at City of Hope (led by Ed Kim, Marwan Fakih, Ashley Baker Lee) that allowed us to sustain robust accrual since enrolling the first patient to this protocol several years ago. But of course, first & foremost, I would like to thank the patients who participated and their families.
Presented at Targets25.”
More posts featuring Sumanta Pal on OncoDaily.